● Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Condition: Prostate Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants700

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (342)

Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Tucson, Arizona, United States	Withdrawn
Research Site	La Jolla, California, United States	Recruiting
Research Site	La Jolla, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	San Diego, California, United States	Recruiting
Research Site	San Luis Obispo, California, United States	Recruiting
Research Site	Lakewood, Colorado, United States	Recruiting
Research Site	Hialeah, Florida, United States	Recruiting
Research Site	Jacksonville, Florida, United States	Recruiting
Research Site	Tallahassee, Florida, United States	Withdrawn
Research Site	Tampa, Florida, United States	Recruiting

+ 330 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06952803